Learn More
R&D Systems™ Recombinant Mouse PD-L2/B7-DC Fc Chimera Protein, CF
Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility. Applications: Bioactivity
Supplier: R&D Systems™ 1022PL01M
Description
Measured by its ability to inhibit anti-CD3-induced proliferation of stimulated mouse T cells. The ED50 for this effect is 1-6 μg/mL.Specifications
Q9WUL5 | |
Bioactivity | |
80380 | |
1 mg | |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20°C to -70°C as supplied. 1 month, 2°C to 8°C under sterile conditions after reconstitution. 3 months, -20°C to -70°C under sterile conditions after reconstitution. | |
B7-DC, bA574F11.2, Btdc, Butyrophilin B7-DC, Butyrophilin-like Protein, CD273, CD273 antigen, CD273PD-1 ligand 2,mgC142240, PD-1-ligand 2, PDCD1L2MGC142238, PDCD1LG2, PDL2, PDL2B7DC, PD-L2PDCD1 ligand 2, programmed cell death 1 ligand 2, Programmed death ligand 2 | |
Recombinant Protein | |
Mouse | |
>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie™ Blue Staining. |
Bioactivity | |
Lyophilized from a 0.2 µm filtered solution in PBS. | |
M.W. (Observed): 76 kDa, reducing conditions; M.W. (theoretical): 49 kDa (monomer) | |
Mouse myeloma cell line, NS0-derived mouse PD-L2/B7-DC protein Mouse PD-L2 (Leu20-Arg219) (N-terminus) Accession # Q9WUL5 IEGRMD Human IgG1 (Pro100-Lys330) (C-terminus) | |
<0.01 EU / 1 µg of the protein by the LAL method. | |
Pdcd1lg2 | |
Unconjugated | |
Reconstitute at 400 µg/mL in sterile PBS. | |
PD-L2/B7-DC/PDCD1LG2 |
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.